Do genes change how tirzepatide works?

Two people start tirzepatide at the same dose and titrate on the same schedule. One loses a fifth of their body weight and barely notices a side effect. The other stalls early and spends the first month fighting nausea. Some of that gap is behaviour, some is baseline physiology, and a 2026 review in the Journal of the Endocrine Society asks how much of it might be written into the genes that code for the drug's target receptors^[1].

What the review actually looked at

Sandro La Vignera and Rosita Condorelli ran a systematic literature search through May 2026, pulling together the genetic studies that test whether inherited variants in the GLP-1 and GIP receptors change how people respond to incretin drugs like tirzepatide and semaglutide. These receptors are the exact proteins the drugs bind to, so the logic is straightforward: if a gene variant slightly reshapes the receptor, it could shift how strongly the drug acts on the person carrying it^[1]. The review is a synthesis of small human studies and mechanism work, not a new trial, and that matters for how much weight to give it.

The GLP-1 receptor variants

Two GLP1R variants come up repeatedly. The review reports that rs6923761 (Gly168Ser) and rs10305492 (Ala316Thr) can modulate receptor expression, G-protein coupling efficiency, and downstream cAMP signalling, the chain of events that turns a drug binding to the receptor into an effect on blood sugar and appetite^[1]. In practice the signal is faint and inconsistent. A randomised pharmacogenomic trial of liraglutide found that carriers of the rs6923761 A allele lost slightly more body fat over 16 weeks than non-carriers, but the result only approached statistical significance rather than clearing it^[2].

And the picture does not always hold. An earlier study that tracked the same rs6923761 variant through a three-month hypocaloric diet found no association at all between the variant and weight loss or the biochemical changes that came with it^[3]. So the honest reading is that the GLP-1 receptor variants might nudge drug response, the studies are small, and the diet and drug settings do not agree.

The GIP receptor variant and nausea

The more interesting thread runs through the GIP receptor, which is the second target tirzepatide hits and the one semaglutide does not. The review flags rs1800437 (Glu354Gln), a variant carried by roughly 20 percent of people of European ancestry, and links it to an altered incretin effect and a higher reported risk of nausea and vomiting on tirzepatide, with an odds ratio of 1.83^[1]. Gastrointestinal side effects are already the most common reason people stop tirzepatide, so a common variant that shifts that risk is worth watching.

Separate mechanism work backs up the idea that this variant does something real. A 2023 study in Molecular Metabolism showed that the Q354 form of the GIP receptor changes how the receptor is trafficked inside the cell, altering the timing of its signalling in a way that improves glucose tolerance and tracks with lower body mass, even though the same variant carries a higher background risk of type-2 diabetes^[4]. A single letter of genetic code, in other words, can measurably change how this receptor behaves. Whether that reliably translates into a different clinical response to the drug is the open question. For the practical side of these side effects, see the tirzepatide safety notes.

What this does not mean yet

It does not mean you should get genotyped before starting an incretin drug. The review is explicit that pharmacogenomic profiling of GLP1R and GIPR variants holds promise but is not yet clinically actionable, and the authors specifically call for more work in Mediterranean and Italian populations before any of it can guide a prescription^[1]. No regulator lists a genetic test as part of tirzepatide or semaglutide prescribing today, and nothing here changes how the drugs are dosed, which is still done by slow clinical titration against how the individual patient tolerates and responds.

This is educational content, not medical advice. Nothing on this page tells you to start, stop, or change a medicine based on a gene variant. If you are considering an incretin drug, or trying to understand why one is or is not working for you, that conversation belongs with a clinician who knows your history. The regulatory status of tirzepatide across our coverage countries is on the peptide page.